Current care areas with gaps in measurement and the next generation of performance measures, according to Rebecca Snead, RPh, executive vice president and chief executive officer of the National Alliance of State Pharmacy Associations and a member of the board of directors for the Pharmacy Quality Alliance.
Current care areas with gaps in measurement and the next generation of performance measures, according to Rebecca Snead, RPh, executive vice president and chief executive officer of the National Alliance of State Pharmacy Associations and a member of the board of directors for the Pharmacy Quality Alliance (PQA).
Transcript (slightly modified for readability)
Where are there current care gaps with no measures, and how is that being remedied?
I think that there are a lot of areas, but one area in particular where we're extremely focused on is around specialty measures. We've got chronic diseases taht are being treated by incredible products, but we need to make sure that they're doing what we hope they would do in improving patient care. Specialty is definitely a focus area for us.
What is the next generation of performance measures, and how will it differ from current measures?
I think that PQA has done an incredible job of not just capturing that low-hanging fruit of things that were easy to measure—more process measures and intermediate outcome measures—but really getting at trying to look at how we're improving care and measures that will take data points from various sources and build to produce a positive outcome. It's hard, it takes a long time, it takes bringing a lot of partners to the table and discussing what the data means, and where you're going to get it from. And it also takes trust, and I think that's one thing that PQA has done over the last 10 years, is build that trust in all of our partners to be able to be willing to share the data to get to that next level of outcomes measures.
What topics does PQA want to address through its column with The American Journal of Pharmacy Benefits?
We really value the partnership and we are very, very excited to continue. I think that what we would like to see next is really a highlight on the opioid measures that were just approved and a discussion around how the marketplace is contemplating on using those measures and implementing them to be able to get those very effectively and very efficiently into the marketplace.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More